129 related articles for article (PubMed ID: 16171088)
1. [Utilizing synergism].
Krankenpfl J; 2005; 43(4-6):145. PubMed ID: 16171088
[No Abstract] [Full Text] [Related]
2. New combinations in metastatic colorectal cancer: what are our expectations?
Hurwitz H
Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
[No Abstract] [Full Text] [Related]
3. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
Li J
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
[No Abstract] [Full Text] [Related]
4. [Improving longevity in advanced intestinal cancer].
Schmoll HJ
Krankenpfl J; 2005; 43(1-3):48. PubMed ID: 15912837
[No Abstract] [Full Text] [Related]
5. Cetuximab in colon cancer.
Costa AF; Sander GB; Picon PD
N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473024
[No Abstract] [Full Text] [Related]
6. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.
Halama N; Herrmann C; Jaeger D; Herrmann T
Anticancer Res; 2008; 28(6B):4111-5. PubMed ID: 19192669
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab in colon cancer.
Martin MJ
N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473023
[No Abstract] [Full Text] [Related]
8. ERBITUX as a single agent and in combination in colorectal carcinoma.
Expert Rev Anticancer Ther; 2002 Jun; 2(3):242. PubMed ID: 12113039
[No Abstract] [Full Text] [Related]
9. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Saltz LB
Nat Clin Pract Oncol; 2005 Jan; 2(1):20-1. PubMed ID: 16264850
[No Abstract] [Full Text] [Related]
10. New treatment options for colorectal cancer.
Erlichman C; Sargent DJ
N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
[No Abstract] [Full Text] [Related]
11. Bevacizumab in colorectal cancer.
Sharieff W
N Engl J Med; 2004 Oct; 351(16):1690-1; author reply 1690-1. PubMed ID: 15490497
[No Abstract] [Full Text] [Related]
12. Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Kabbinavar F; Kozloff M
Oncology; 2011; 80(1-2):135-7; author reply 140-1. PubMed ID: 21677459
[No Abstract] [Full Text] [Related]
13. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
[TBL] [Abstract][Full Text] [Related]
14. Validation of the role of angiogenesis as a chemotherapeutic target.
Chu E
Clin Colorectal Cancer; 2003 Aug; 3(2):74-5. PubMed ID: 12952560
[No Abstract] [Full Text] [Related]
15. Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.
Ku GY; Krol G; Ilson DH
J Clin Oncol; 2007 May; 25(13):e14-6. PubMed ID: 17470852
[No Abstract] [Full Text] [Related]
16. Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Boisen MK; Johansen JS; Larsen O; Jensen BV
Oncology; 2011; 80(1-2):138-9. PubMed ID: 21677460
[No Abstract] [Full Text] [Related]
17. The price tag on progress--chemotherapy for colorectal cancer.
Schrag D
N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
[No Abstract] [Full Text] [Related]
18. Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract.
Mahtani RL; Macdonald JS
Oncologist; 2008 Jan; 13(1):39-50. PubMed ID: 18245011
[TBL] [Abstract][Full Text] [Related]
19. Erbitux trial flawed from the beginning, committee finds.
Randal J
J Natl Cancer Inst; 2002 Dec; 94(24):1824-5. PubMed ID: 12488469
[No Abstract] [Full Text] [Related]
20. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
